Condition: Hypotension · Sponsor: West-Ward Pharmaceutical
The primary objective of this study is to evaluate the dose effect of Phenylephrine Hydrochloride Injection on the treatment of clinically relevant decreased blood pressure in the pediatric population, ≥12 to 16 year old patients undergoing general and neuraxial anesthesia. The secondary objectives are to describe changes in blood pressure and heart rate, time to onset and to maximal response, and the duration of response; to assess the safety of the product in this population; and to characterize the pharmacokinetics of phenylephrine hydrochloride.
This description comes directly from the study's public registry record.
J. Barton Kalis · 856-489-2247 · jkalis@hikma.com
Always discuss trial participation with your own doctor first.
| Alfred I. DuPont Hospital for Children | Wilmington, Delaware, United States | Withdrawn |
| Children's National Medical Center | Washington D.C., District of Columbia, United States | Terminated |
| Jackson Memorial Hospital | Miami, Florida, United States | Recruiting |
| Children's Healthcare of Atlanta at Egleston | Atlanta, Georgia, United States | Terminated |
| University of Mississippi Medical Center | Jackson, Mississippi, United States | Terminated |
| Stony Brook Medicine | Stony Brook, New York, United States | Terminated |
| Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
| Children's Medical Center of Dallas | Dallas, Texas, United States | Recruiting |
| Seattle Children's Hospital | Seattle, Washington, United States | Withdrawn |
| Ruby Memorial Hospital | Morgantown, West Virginia, United States | Terminated |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02323399